Glenmark evaluating legal options over diabetes drugs setback

As per HC's order, company has been restrained from manufacturing and selling generic version of MSD's anti-diabetes medicines

Drug firm Glenmark Pharmaceuticals today said it is evaluating legal options after the Delhi High Court restrained it from manufacturing and selling generic version of MSD's anti-diabetes medicines Januvia and Janumet.

"Glenmark accepts the Honourable High Court's decision. However the decision can be appealed and Glenmark is evaluating the possible legal options," the company said in a filing to the BSE.

As per the High Court's Order yesterday, "Glenmark has been restrained by a decree of permanent injunction from making, using, selling, distributing, advertising, exporting, offering for sale or dealing in Sitagliptin Phosphate Monohydrate or any other salt of Sitagliptin in any form, alone or in combination with one or more other drugs".
 

Pharma major Merck Sharp and Dohme (MSD) in its plea had sought injunction against Glenmark alleging that the Indian pharma company had violated its IPR over its anti-diabetes medicines, Januvia and Janumet, by coming out with their own drugs containing the same salts.

Shares of Glenmark Pharmaceuticals closed at Rs 993.20 per scrip on BSE, down 3.84 per cent from previous close.